on MEDESIS S.A. (isin : FR0010844464)
MEDESIS PHARMA: Judicial liquidation procedure opened
MEDESIS PHARMA, a pharmaceutical biotechnology company, has announced the opening of liquidation proceedings. This decision was made by the Montpellier Commercial Court on March 7, 2025. The company had initially initiated safeguard proceedings on September 29, 2023, which were converted into receivership on November 8, 2024. The lack of prospects for reorganizing the company led to this final act.
As a result, MEDESIS PHARMA's shares were suspended on March 10, 2025. The company's assets may not be sufficient to repay shareholders. Aonys® technology, while promising, has not prevented this fate. Investors are informed of the risks associated with the company's liabilities.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDESIS S.A. news